Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,640.0 million
Deal Type : Collaboration
AbbVie Crafts $1.6B Deal with Molecular Glue Biotech Neomorph
Details : The collaboration leverages AbbVie's oncology and immunology drug development expertise and Neomorph's leading molecular glue discovery platform.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : $1,640.0 million
Deal Type : Collaboration
Lead Product(s) : Molecular Glue Degrader-based Therapy
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Biogen
Deal Size : $1,450.0 million
Deal Type : Collaboration
Biogen & Neomorph Announce Collaboration to Discover and Develop Molecular Glue Degraders
Details : The collaboration aims to leverage Neomorph's proprietary molecular glue discovery platform to expedite the identification and validation of new small-molecule therapeutics for Alzheimer’s disease.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : Molecular Glue Degrader-based Therapy
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Biogen
Deal Size : $1,450.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $1,460.0 million
Deal Type : Collaboration
Neomorph Announces Collaboration with Novo Nordisk to Discover Molecular Glue Degraders
Details : The collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $1,460.0 million
Deal Type : Collaboration